<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851237</url>
  </required_header>
  <id_info>
    <org_study_id>201807099</org_study_id>
    <secondary_id>1R01CA235672-01</secondary_id>
    <nct_id>NCT03851237</nct_id>
  </id_info>
  <brief_title>CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy</brief_title>
  <official_title>Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently there is no clinical biomarker that can be used to select patients for
      CCR2-targeted therapy and to monitor response to such therapy. Considering the toxicity and
      the rate of response to CCR2-targeted therapy, it is crucial to be able to identify patients
      who may not response to this therapy in order to avoid the morbidity and expense associated
      with ineffective therapy.

      Therefore, the combination of the novel CCR2 imaging agent with the novel CCR2-targeted
      therapy in this trial is of great importance to promote science while prolonging the life and
      its quality in patients with PDAC. The investigators also believe that this combination will
      make substantial contributions to the fields of cancer immunotherapy and tumor
      monocyte/macrophage biology. Moreover, this imaging agent has the potential to not only
      facilitate development and testing of future CCR2-targeted therapeutic agents but also serve
      as a prescreen tool to select appropriate patients for imaging guided treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects enroll to 1 of 2 cohorts. Cohort 1 is subdivided to cohort 1A and enrolls
      subjects with a new diagnosis of pancreatic cancer scheduled to undergo surgical resection.
      Cohort 1A subjects undergo 1 imaging session which consists of 1 injection of 64Cu-DOTA-ECL1i
      followed by PET/CT imaging at 2 time points: immediately following injection and 75 minutes -
      6 hours post injection. Cohort 1B subjects are newly diagnosed, recurrent or metastatic
      pancreatic cancer patients scheduled to undergo treatment with standard of care therapy.
      Cohort 1B subjects undergo 1 imaging session (same as cohort 1A) prior to beginning therapy
      and a second imaging session either half way through therapy or at recurrence depending on
      the results of the first imaging session. Cohort 2 subjects are newly diagnosed pancreatic
      cancer patients scheduled to undergo treatment with a CCR2 inhibitor under a companion
      treatment protocol. Cohort 2 subjects undergo 1 imaging session prior to beginning therapy
      and a second imaging session after 2 cycles of therapy. All enrolled subjects who have tissue
      available for testing from biopsy or surgical resection consent to tissue testing for
      correlative studies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether 64Cu-DOTA-ECL1i detects CCR2 expression in PDAC tumors as measured by direct comparison of visual tumor uptake on 64Cu-DOTA-ECL1i images to CCR2 measurements in surgical specimens</measure>
    <time_frame>Completion of first scan (day 1)</time_frame>
    <description>Visual tumor uptake as compared to background blood/tissue uptake: 1=no uptake, 2=mild uptake, 3=moderate uptake, and 5=striking update
Will utilize published methods of immunohistochemical staining techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1b only: Evaluate whether tumor uptake of 64Cu-DOTA-ECL1i prior to therapy predicts response to standard of care chemotherapy as measured by tumor SUVmax</measure>
    <time_frame>Completion of first scan (day 1)</time_frame>
    <description>SUVmax is a mathematical measurement of tumor burden seen on images and calculated by the following equation SUVmax= r / (a'/w) where r= radioactivity concentration in tumor (kBq/ml) as measured by the PET scanner within a defined region of interest, a'=the decay corrected amount of injected 64Cu-DOTA-ECL1i and w= weight of the patient in grams When PET imaging shows uptake of 64Cu-DOTA-ECL1i in site(s) of known tumor the SUVmax will be compared to clinical measurement of response to treatment taking into consideration standard response criteria including radiological imaging, laboratory values, physical examination and repeat pathology as applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate whether tumor take of 64Cu-DOTA-ECL1i post therapy correlates with CCR2 expression and is predictive of response to therapy as measured by visual tumor uptake on 64Cu-DOTA-ECL1i images</measure>
    <time_frame>Baseline and after 2 cycles of CCR directed therapy (estimated to be 2 months)</time_frame>
    <description>Visual tumor uptake as compared to background blood/tissue uptake: 1=no uptake, 2=mild uptake, 3=moderate uptake, and 5=striking update
A decrease in visual tumor uptake from baseline to post therapy imaging in cohort 2 subject is hypothesized to represent response to CCR2 directed therapy while an increase in tumor uptake is expected in cohort 1b subjects who progress while receiving standard therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate if tumor take of 64Cu-DOTA-ECL1i is predictive of response to CCR2-directed therapy measured by comparison of SUVmax at imaging prior to the start of CCR2 directed therapy and SUVmax at imaging performed after 2 cycles of CCR2 directed therapy</measure>
    <time_frame>Baseline and after 2 cycles of CCR2 directed therapy (estimated to be 2 months)</time_frame>
    <description>Cohort 2 only
SUVmax is a mathematical measurement of tumor burden seen on images and calculated by the following equation SUVmax= r / (a'/w) where r= radioactivity concentration in tumor (kBq/ml) as measured by the PET scanner within a defined region of interest, a'=the decay corrected amount of injected 64Cu-DOTA-ECL1i and w= weight of the patient in grams When PET imaging shows uptake of 64Cu-DOTA-ECL1i in site(s) of known tumor the SUVmax will be evaluated for change at baseline and after 2 cycles of CCR2 directed therapy. SUVmax measurements will also be compared to clinical measurement of response to treatment taking into consideration standard response criteria including radiological imaging, laboratory values, physical examination and repeat pathology as applicable</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1a: Standard of Care Whipple Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care diagnostic biopsy
64Cu-DOTA-ECL1i-PET/CT imaging - immediately after the dynamic study
Standard of care Whipple procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b: Standard of Care Treatment Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care diagnostic biopsy (tissue to be used for CCR2 expression)
64Cu-DOTA-ECL1i-PET/CT imaging pretherapy
2-3 cycles of standard of care (SOC) chemotherapy
Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with metastatic disease who progressed on SOC chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: CCR2-Targeted Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biopsy per therapeutic protocol (tissue to be used for CCR2 expression)
64Cu-DOTA-ECL1i-PET/CT imaging pretherapy
2 cycles of CCR2-targeted therapy
Biopsy per therapeutic protocol (tissue to be used for CCR2 expression) --Additional 64Cu-DOTA-ECL1i-PET/CT imaging after 2 cycles of therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-DOTA-ECLIi</intervention_name>
    <description>-The first five patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i</description>
    <arm_group_label>Cohort 1a: Standard of Care Whipple Treatment</arm_group_label>
    <arm_group_label>Cohort 1b: Standard of Care Treatment Chemotherapy</arm_group_label>
    <arm_group_label>Cohort 2: CCR2-Targeted Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CTI/Siemens Biography 40 PET/CT</intervention_name>
    <description>-Standard of care</description>
    <arm_group_label>Cohort 1a: Standard of Care Whipple Treatment</arm_group_label>
    <arm_group_label>Cohort 1b: Standard of Care Treatment Chemotherapy</arm_group_label>
    <arm_group_label>Cohort 2: CCR2-Targeted Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 18 years of age or older with newly diagnosed early-staged localized
             pancreatic ductal adenocarcinoma (PDAC) (cohort 1a), borderline resectable, locally
             advanced, or metastatic PDAC (cohort 1b) or borderline resectable, locally advanced
             (cohort 2) with at least one measurable [defined as lesions that can be accurately
             measured in at least one dimension (longest diameter to be recorded) as â‰¥ 10 mm with
             CT scan or MRI]

          -  Must be eligible to undergo Whipple procedure (cohort 1a) and/or standard chemotherapy
             including FLFIRINOX or gemcitabine/nab-paclitaxel (Cohort 1b) OR eligible or signed
             consent to undergo CCR2-targeted therapy example:[(phase 1/2 clinical trial combining
             an oral CCR2/5i (BMS-813160) with chemotherapy (gemcitabine plus nab-paclitaxel) and
             anti-PD-1 (nivolumab), PI, Dr. Kian Lim) HRPO #201806007] (Cohort 2)

          -  Able to give informed consent

          -  Not currently pregnant or nursing: Subject must be surgically sterile (has had a
             documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal
             (cessation of menses for more than 1 year), non-lactating, or of childbearing
             potential for whom a urine pregnancy test (with the test performed within the 24 hour
             period immediately prior to administration of 64Cu-DOTA-ECL1i) is negative

        Exclusion Criteria:

          -  Patients with other invasive malignancies, with the exception of non-melanoma skin
             cancer, who had (or have) any evidence of the other cancer present within the last 5
             years

          -  Unable to tolerate up to 90 min of PET/CT imaging per imaging session.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farrokh Dehdashti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

